Head And Neck Squamous Cell Carcinoma Clinical Trials
Here are the 6 most popular medical studies for head and neck squamous cell carcinoma
Virus Therapy
TAK-676 + Pembrolizumab for Cancer
This trial is testing a combination of two immunotherapy drugs, TAK-676 and pembrolizumab, to see if they can improve outcomes for people with non-small cell lung cancer, triple-negative breast cancer, and squamous cell carcinoma of the head and neck.
Small Molecule Inhibitor
NT219 + Cetuximab for Head and Neck Cancer
This trial is testing a new drug, NT219, to see if it is safe and effective against solid tumors. The trial will have two parts, first testing different doses of NT219 to see what is safe, then testing NT219 with another drug, ERBITUX, to see if it is more effective than ERBITUX alone.
Monoclonal Antibodies
REGN6569 + Cemiplimab for Advanced Solid Cancer
This trial is evaluating the safety and efficacy of REGN6956 as monotherapy and in combination with cemiplimab. The primary objective is to assess the safety and tolerability of the combination. Secondary objectives include assessing the preliminary efficacy of the combination as measured by objective response rate, disease control rate, duration of response, progression-free survival, and overall survival.
Popular filter options for head and neck squamous cell carcinoma trials
Squamous Cell Carcinoma Clinical Trials
View 56 Squamous Cell Carcinoma medical studies.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
SCC Clinical Trials
View 53 SCC medical studies.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
P16 Positive Clinical Trials
View 6 p16 positive medical studies.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
Cytokine Agonist
SAR444245 + Anticancer Therapies for Head and Neck Cancer
This trial is investigating whether the drug SAR444245, when combined with other cancer treatments, will result in a significant increase in the number of people with head and neck squamous cell carcinoma (HNSCC) who respond to the treatment. The trial is divided into three parts, each testing the drug in combination with a different treatment. Part 1 is testing SAR444245 combined with the anti-PD1 antibody pembrolizumab in people who are treatment-naive for recurrent and/or metastatic HNSCC. Part 2 is testing SAR444245 combined with the anti-PD1 antibody pembrolizumab in
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Apoptosis Inhibitor
Xevinapant + Chemoradiation for Head and Neck Cancer
This trial will test a new drug (xevinapant) combined with chemotherapy and radiation to fight head and neck cancer. Participants will get up to 4 doses to determine the safest dose, then a larger group will try that dose.
Monoclonal Antibodies
Imatinib + Cetuximab for Head and Neck Cancer
This trial tests whether a protein in cancer cells can predict how head and neck tumors respond to a combination of two treatments. Participants will be monitored for 13-16 months to assess the effectiveness.
Phase 3 Head And Neck Squamous Cell Carcinoma Clinical Trials
View 97 phase 3 head and neck squamous cell carcinoma medical studies.
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Hormone Therapy
Hormone Therapy + Immunotherapy for Advanced Breast Cancer
This trial is testing tamoxifen citrate or letrozole with or without bevacizumab to treat stage IIIB or IV breast cancer. Estrogen fuels breast cancer cell growth, so hormone therapy with tamoxifen or letrozole can block estrogen and stop tumor growth. Bevacizumab is an immunotherapy that may help the body's immune system fight the cancer. Researchers want to see if it is more effective with or without bevacizumab.
Alkylating agents
Chemotherapy + Bevacizumab for Head and Neck Cancers
This trial is testing chemotherapy with or without bevacizumab to see how well it works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other parts of the body.
Head And Neck Squamous Cell Carcinoma Clinical Trials With No Placebo
View 97 head and neck squamous cell carcinoma medical studies that do not have a placebo group.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
View More Head And Neck Squamous Cell Carcinoma Trials
See another 67 medical studies focused on head and neck squamous cell carcinoma.
Frequently Asked Questions
Introduction to head and neck squamous cell carcinoma
What are the top hospitals conducting head and neck squamous cell carcinoma research?
When it comes to cutting-edge clinical trials for head and neck squamous cell carcinoma, several top hospitals are leading the way in research and innovation. Located in Duarte, California, City of Hope Comprehensive Cancer Center offers an impressive 19 ongoing trials focused specifically on this type of cancer. While they have yet to conduct any previous studies in this area, their dedication to combating head and neck squamous cell carcinoma is evident.
Similarly committed to finding new treatments and strategies is the University of California Davis Comprehensive Cancer Center in Sacramento. With 19 active clinical trials solely dedicated to head and neck squamous cell carcinoma, they too have not conducted any previous studies but remain steadfast in their pursuit of advancements.
Heading over to Houston, Texas, we find M D Anderson Cancer Center making significant strides with 18 ongoing clinical trials for head and neck squamous cell carcinoma. Like the other hospitals mentioned above, they also do not have a recorded history of past trials specific to this condition; however, their current efforts showcase their commitment towards future breakthroughs.
Closer to Los Angeles lies Providence Saint Joseph Medical Center/Disney Family Cancer Center located in Burbank where researchers are actively conducting 18 clinical trials focusing on head and neck squamous cell carcinoma treatment without having carried out prior investigations thus far.
Finally reaching Berkeley's Alta Bates Summit Medical Center-Herrick Campus which contributes significantly as well through its participation involving seventeen concurrent tests pertaining exclusively towards patients suffering from Head & Neck Squamous Cell Carcinoma despite lack historical data regarding earlier undertakings until now
These esteemed institutions serve as beacons of hope for those battling or affected by head and neck squamous cell carcinoma. Through collaborative efforts within these medical centers across various locations nationwide there exists strong belief that every trial brings us closer towards pioneering discoveries that would potentially revolutionize treatment options available thereby enhancing quality life countless individuals grappling such ailment face
Which are the best cities for head and neck squamous cell carcinoma clinical trials?
When it comes to head and neck squamous cell carcinoma clinical trials, several cities in the United States emerge as key hubs for research and treatment. Anchorage, Alaska boasts an impressive 84 active trials, focusing on the efficacy of Bevacizumab, Tamoxifen Citrate, Arm III (anastrozole and fulvestrant), among others. Oakland, California follows closely behind with 75 ongoing studies exploring treatments such as Bevacizumab, Trastuzumab, Paclitaxel. Additionally, Denver, Colorado has 73 active trials investigating the potential benefits of Bevacizumab,Paclitaxel,Therapeutic Conventional Surgery,and more. These cities offer individuals diagnosed with head and neck squamous cell carcinoma access to cutting-edge clinical trials that pave the way for advancements in care and improved outcomes.
Which are the top treatments for head and neck squamous cell carcinoma being explored in clinical trials?
Clinical trials for head and neck squamous cell carcinoma are investigating several promising treatments. Leading the pack is pembrolizumab, a groundbreaking immunotherapy drug that has shown significant efficacy in multiple trials. Another contender is cetuximab, a targeted therapy specifically designed to tackle this type of cancer. Additionally, researchers are exploring the potential of combination therapies such as docetaxel plus cisplatin and radiation therapy with chemotherapy drugs like fluorouracil. These innovative approaches bring hope for improved outcomes in patients battling head and neck squamous cell carcinoma.
What are the most recent clinical trials for head and neck squamous cell carcinoma?
Promising advancements in the treatment of head and neck squamous cell carcinoma have emerged from recent clinical trials. In particular, Nivolumab has shown encouraging results as a potential therapy for this type of cancer. Additionally, various treatment combinations involving cisplatin, docetaxel, nintedanib, crizotinib, erlotinib hydrochloride, and nab-paclitaxel are being investigated to improve outcomes for patients with head and neck squamous cell carcinoma. These trials offer hope for enhanced therapeutic options that can make a significant difference in the lives of individuals affected by this challenging disease.
What head and neck squamous cell carcinoma clinical trials were recently completed?
Several clinical trials focusing on head and neck squamous cell carcinoma have recently concluded, showcasing advancements in treatment options for this aggressive form of cancer. Notably, a trial sponsored by the University of Texas MD Anderson Cancer Center investigating pembrolizumab reached completion in September 2021. Another significant milestone was achieved with the conclusion of a study led by Memorial Sloan Kettering Cancer Center, evaluating the efficacy of nivolumab combined with ipilimumab in treating advanced-stage head and neck squamous cell carcinoma. These completed trials demonstrate ongoing efforts to improve outcomes and enhance therapeutic strategies against this challenging disease.